Goldman Sachs Group Inc Sarepta Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 477,066 shares of SRPT stock, worth $50.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
477,066
Previous 301,021
58.48%
Holding current value
$50.9 Million
Previous $37.6 Million
54.28%
% of portfolio
0.01%
Previous 0.01%
Shares
20 transactions
Others Institutions Holding SRPT
# of Institutions
535Shares Held
87.4MCall Options Held
1.55MPut Options Held
1.35M-
Black Rock Inc. New York, NY10.3MShares$1.1 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$970 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA8.7MShares$928 Million0.21% of portfolio
-
Janus Henderson Group PLC London, X04.33MShares$462 Million0.28% of portfolio
-
State Street Corp Boston, MA4.07MShares$434 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $9.35B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...